NMDP/Be The Match® PTCy Research Levels the Field between Matched and Mismatched Hematopoietic Cell Transplantation
11 déc. 2023 15h00 HE
|
Be The Match
The study shows the practice-changing potential of using mismatched unrelated donors to expand access to all patients regardless of ancestry.
Phase III Clinical Trial Published in New England Journal Of Medicine Identifies New Standards for Prevention of Graft Versus Host Disease Following Transplant
22 juin 2023 11h00 HE
|
Be The Match
MINNEAPOLIS, June 22, 2023 (GLOBE NEWSWIRE) -- Results of a Phase III randomized clinical trial published in the New England Journal of Medicine indicates that a new strategy for prevention of graft...
DelveInsight Estimates a Promising Picture of Graft vs. Host Disease Pipeline Space Landscape as Key 60+ Pharma Companies Working in the Space
09 nov. 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- DelveInsight Estimates a Promising Picture of Graft vs. Host Disease Pipeline Space Landscape as Key 60+ Pharma Companies Working in the Space The...
ExCellThera announces oral presentation of new data on UM171-expanded cell therapy at the ASH Annual Meeting
04 nov. 2022 09h30 HE
|
ExCellThera
MONTREAL, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that an abstract related to ExCellThera’s...
Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA
12 juil. 2021 16h01 HE
|
Equillium
Single pivotal Phase 3 study in acute graft-versus-host disease tosupport filing of biologics license application On track to initiate study in Q4 2021 LA JOLLA, Calif., July 12, 2021 (GLOBE...
Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease
11 juin 2021 07h00 HE
|
Equillium
Itolizumab continues to demonstrate favorable safety and efficacy profile Rapid and durable responses resulted in clinically meaningful reduction in corticosteroid use Data support clinical...
Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11
03 juin 2021 08h00 HE
|
Equillium
Presentation and conference call will include topline data from all cohorts The risk-benefit profile observed supports advancing development of itolizumab in first-line therapy LA JOLLA,...
Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association
13 mai 2021 08h00 HE
|
Equillium
LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
15 mars 2021 08h00 HE
|
Equillium
EQUATE acute graft-versus host disease (aGVHD) study observed rapid response and durability through day 85 EQUATE aGVHD study reported a clinically meaningful reduction in corticosteroid...
Equillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference
18 févr. 2021 08h00 HE
|
Equillium
LA JOLLA, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...